Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Key differences found between pediatric- and adult-onset MS

Key clinical point: Pediatric-onset MS has a unique phenotype, and the choice of treatment may influence the frequency of fatigue and mood disorders among these patients.

Major finding: Anxiety and fatigue were associated with disease-modifying therapy efficacy in pediatric-onset MS.

Study details: An analysis of data from MS Partners Advancing Technology and Health Solutions (MS-PATHS).

Disclosures: Biogen sponsors MS-PATHS. Dr. Rensel has received funding from several companies, including Biogen, Novartis, Serono, and Teva.


Rensel M et al. ACTRIMS 2020, Abstract P042.